Korsana Biosciences emerged with $175M to develop KRSA-028, a brain-penetrant Alzheimer's antibody u...
The AMW Read
The article introduces a new player in the specialized neuro-therapeutic space, but the $175M funding round does not meet the $500M threshold for a cross.§D capital cycle tag.
NoveltySignificance
Healthcare & Bio · Player Map
Korsana Biosciences emerged with $175M to develop KRSA-028, a brain-penetrant Alzheimer's antibody using THETA technology that shuttles drugs across the blood-brain barrier via transferrin receptor targeting. The blood-brain barrier shuttle race is intensifying with Roche's trontinemab in late-stage trials and AbbVie's $1.4B Aliada acquisition validating this approach. Korsana differentiates with monthly subcutaneous dosing versus intravenous administration, potentially improving patient access. Safety data expected mid-2027 could position this as a next-generation therapy addressing current limitations of approved anti-amyloid drugs.
